MedTrace Logo

Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD

NCT04167189 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-07-02

Study results available
· View outcomes & findings →

Summary

This work will assess the prevalence in hard-to-treat ADHD of the ineffectiveness of the anesthetic Lidocaine.

Conditions

  • ADHD

Interventions

DRUG

Lidocaine gel

Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg

Sponsors & Collaborators

  • NeurAbilities (formerly CRCNJ)

    collaborator OTHER

  • PhenoSolve, LLC

    lead INDUSTRY

Principal Investigators

  • Michael Segal, MD PhD · PhenoSolve, LLC

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-20
Primary Completion
2020-03-30
Completion
2020-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04167189 on ClinicalTrials.gov